The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

zosanopharma.com

Founded Year

2006

Stage

IPO | IPO

Total Raised

$109.23M

Date of IPO

1/27/2015

Market Cap

0.01B

Stock Price

2.10

Revenue

$0000 

About Zosano Pharma

Zosano Pharma is a clinical-stage biopharmaceutical company enabling the systemic administration of therapeutics and other bioactive molecules to patients using our proprietary intracutaneous microneedle patch system. We have pioneered a novel paradigm for delivering molecules typically administered parenterally, where the inconvenience and pain associated with subcutaneous, intravenous or other complex administrations present barriers to compliance. Our strengths lie in our diverse team of industry veterans with proven drug and device development and significant commercialization experience.

Zosano Pharma Headquarter Location

34790 Ardentech Court

Fremont, California, 94555,

United States

510-745-1200

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Zosano Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Zosano Pharma is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Zosano Pharma Patents

Zosano Pharma has filed 6 patents.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Piperazines
  • Piperidines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/29/2018

7/13/2021

Serotonin receptor agonists, Piperidines, Piperazines, Fluoroarenes, Amines

Grant

Application Date

1/29/2018

Grant Date

7/13/2021

Title

Related Topics

Serotonin receptor agonists, Piperidines, Piperazines, Fluoroarenes, Amines

Status

Grant

Latest Zosano Pharma News

Emergex Vaccines Announces the Successful Coating of its Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch

May 17, 2022

Novel CD8+ T cell Adaptive COVID-19 Vaccine onto Zosano Pharma’s Micro-Needle Patch Emergex’s COVID-19 and Dengue CD8+ T cell Adaptive vaccines are already in clinical trials Abingdon, Oxon, UK, 17th May 2022 – Emergex Vaccines Holding Limited (‘Emergex’, or the ‘Company’), a clinical stage biotechnology company addressing major global infectious diseases through the development of fully synthetic CD8+ T cell Adaptive Vaccines, today announced that its COVID-19 vaccine candidate has been successfully coated onto Zosano Pharma Corporation’s (NASDAQ:ZSAN) proprietary microneedle patch system. Zosano’s patch consists of an array of approximately two thousand drug-coated titanium microneedles mounted on an adhesive patch that is administered to the skin using a reusable applicator. Emergex and Zosano have demonstrated that Emergex’s COVID-19 vaccine is stable on the patches over a wide temperature range for up to six months at 40oC/75% relative humidity. Reducing cold chain logistics to a minimum may allow less costly and efficient vaccination programs around the world and increase global preparedness for future pandemics and disease outbreaks. Emergex CD8+ T cell Adaptive Vaccine for COVID-19 offers the potential for long-term immune protection, thereby avoiding the need for seasonal boosting, and its broad protection is less likely to be impacted by changes (mutations) in the consensus sequence in RNA viruses leading to new variants of concern. Combining Emergex’s novel vaccine platform with Zosano’s innovative microneedle patch brings innovation in both immunological protection and delivery routes which may benefit global communities across many different infectious diseases. Mahmoud Ameri, Ph.D., Vice President of research and development at Zosano, commented: “We are pleased to have successfully reached this six-month milestone with a COVID-19 vaccine candidate onto our microneedle patch system and to collaborate with Emergex.” Robin Cohen, Chief Commercial Officer at Emergex, commented: “Vaccine delivery is a critical component in the global effort both to prepare for future pandemics and to prevent disease outbreaks in communities around the world. Our T cell Adaptive Vaccine technology has the potential to provide broad immune protection – covering viral strains and escape mutations as well as cellular immune memory that may last for decades. Combining this ground-breaking approach to vaccination with innovative, easy-to-use patch delivery could radically transform the vaccine landscape. We are delighted to have worked with Zosano on this exciting project.” - Ends - About Emergex Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of 100% synthetic T cell Adaptive Vaccines that harness the body’s natural T cell immune response to destroy pathogen-infected cells in order to provide protection against some of the world’s most pressing health threats: [i] viral infectious diseases, amongst which are Dengue, Coronaviruses, and pandemic Influenza, as well as [ii] serious intracellular bacterial infectious diseases. Emergex has a growing proprietary pipeline of innovative CD8+ T cell Adaptive Vaccine and booster vaccine candidates that have the potential to deliver rapid, broad (mutation-agnostic) and long-lasting immunity to reduce serious illness associated with infectious disease. Emergex has a number of Phase I clinical trials underway, of which the most advanced programmes in development are [i] Dengue (which may also be disease-modifying for other members of the Flaviviridae virus family, such as Zika and Yellow Fever) and [ii] Coronaviruses. Other programmes in development include vaccine candidates for universal (pandemic) Influenza, Chikungunya, and a booster vaccine for Yellow Fever. Emergex’s T cell Adaptive Vaccines candidates combine two proprietary technologies, [i] an empirically determined library of pathogen-derived protein fragments expressed on the surface of pathogen-infected cells (forming the MHC Class I expression “ligandome” library), and [ii] a passivated gold nanoparticle carrier system designed to deliver the synthetic peptides to the skin-resident immune system (in combination with nociception) via microneedles in order to elicit a robust, adaptive CD8+ T cell response. With potential stability at ambient temperatures, the vaccine candidates are intended to reduce the burden and the logistics of vaccine administration. Find out more online at  www.emergexvaccines.com . About Zosano Pharma Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Learn more at www.zosanopharma.com . Forward-Looking Statements This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding efficiency, cost and potential of Emergex’s vaccination program, the benefits and potential uses of Zosano Pharma’s transdermal microneedle system and other future events and expectations described in this press release. Readers are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “might,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “scheduled,” “goal,” “approximately” or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict, and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the company’s ability to continue operations, successfully restructure its indebtedness or complete any strategic transactions and other risks and uncertainties described under the heading “Risk Factors” in the company’s most recent annual report on Form 10-K and quarterly reports on Form 10-Q. Although Zosano believes that the expectations reflected in these forward-looking statements are reasonable, Zosano cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.

Zosano Pharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Zosano Pharma Rank

  • When was Zosano Pharma founded?

    Zosano Pharma was founded in 2006.

  • Where is Zosano Pharma's headquarters?

    Zosano Pharma's headquarters is located at 34790 Ardentech Court, Fremont.

  • What is Zosano Pharma's latest funding round?

    Zosano Pharma's latest funding round is IPO.

  • How much did Zosano Pharma raise?

    Zosano Pharma raised a total of $109.23M.

  • Who are Zosano Pharma's competitors?

    Competitors of Zosano Pharma include Prevtec Microbia, Intarcia Therapeutics, BioCardia, Alexza Pharmaceuticals, Radius Health, NeurOP, NuPathe, Santarus, Acton Pharmaceuticals, MAP Pharmaceuticals and 19 more.

You May Also Like

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

S
SoluBest

SoluBest is a clinical stage pharmaceutical company developing nanoformulations of existing therapeutic medicines in several fields. Solubest uses its advanced polymer formulations to prepare nano-particles of drugs with delivery or compliance insufficiencies. SoluBest's pipeline of existing off-patent drugs are being re-formulated for:nn * its own product developmentn * co-development partners

V
Valens Therapeutics

Valens Therapeutics is a pharmaceutical company focused on the development of therapeutic products for the treatment of neovascular diseases including certain pathological conditions in the eye and cancer. The company's initial focus is on ophthalmologic disorders caused by unregulated angiogenesis and which offer major opportunities for improved therapies. The ultimate goal is to offer a platform technology of multiple indications for both the ophthalmology and oncology markets. The company's business strategy also includes providing to scientists in the private, government and academic sectors full access to a GMP qualified cleanroom suite for the manufacturing of biologics

T
Tempo Pharmaceuticals

Tempo Pharmaceuticals is developing a nanoparticle technology designed to improve the safety and efficacy of marketed and development-stage drugs.

Banyan Biomarkers Logo
Banyan Biomarkers

Banyan Biomarkers has created a Point of Care (POC) Blood Test to diagnose traumatic brain injury (TBI). Banyan Biomarkers' research has identified unique biomarkers present in the patient's blood following injury to the brain. The detection and quantification of these biomarkers may provide early indications of brain trauma essential for earlier intervention and management.

M
MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost-effectiveness of its product candidates.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.